Plegridy (Peginterferon)

What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.

Coming Soon – Save up to 85%

Sign up to get exclusive coupon discounts and be the first to be notified when we have this product available.

Prescription Required

  • Product Details

    Description

    Plegridy, known scientifically as Peginterferon beta-1a, is a medication designed for individuals battling relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. This drug acts by modulating the body's immune response, which is crucial in MS where the immune system mistakenly attacks the nervous system. It is part of a group of drugs called interferons, which are proteins that play a role in the immune response. Specifically, Plegridy is delivered via injection and aims to decrease the frequency of relapse episodes and manage the progression of the disease in adults.

    Directions

    When taking Plegridy, it's crucial to follow healthcare provider instructions diligently. For treating relapsing forms of multiple sclerosis, the medication is administered via subcutaneous (under the skin) or intramuscular (into the muscle) injection. The typical regimen begins with a titration period: starting at 63 mcg on day one, increasing to 94 mcg on day 15, and reaching the full 125 mcg dose on day 29, with subsequent doses every 14 days. Regular injection sites include the abdomen or the back of the upper arm.

    For patients new to Plegridy, it is important to be aware of the injection technique, which can affect the likelihood of reactions at the injection site. Always ensure you have clear guidance from your healthcare provider regarding injection procedures and what to watch for in terms of potential side effects.

    Ingredients

    The active ingredient in Plegridy is Peginterferon beta-1a. Inactive ingredients include glacial acetic acid, L-arginine hydrochloride, and polysorbate 20.

    Contraindications

    Patients with a history of hypersensitivity reactions to natural or recombinant interferon beta or any other component of Plegridy are advised not to use this medication.

    Cautions

    • Prior to initiating treatment with Plegridy, make sure to inform your healthcare provider about the following:
      • Any health conditions you have
      • Any allergies
      • The complete list of medications you are currently taking
      • Your pregnancy or breastfeeding status
    • Plegridy can cause significant liver damage, including hepatitis and severe liver failure. Some patients may only show elevated liver enzymes, which indicates liver stress. Regular liver function tests are essential to monitor your liver health.
    • Patients using Plegridy may experience an increase in depression and suicidal thoughts. It’s critical to report any changes in mood or new mental health symptoms to your healthcare provider immediately.
    • Severe allergic reactions, including anaphylaxis, can occur with Plegridy. If you experience severe symptoms like swelling, difficulty breathing, or intense rashes, seek emergency medical help right away.
    • Reactions at the site of injection, including redness, pain, or swelling are common. Severe reactions, such as tissue death (necrosis), though rare, require prompt medical attention.
    • Plegridy can worsen or lead to new heart issues, such as congestive heart failure. Patients with pre-existing heart conditions should be closely monitored during treatment.
    • Treatment with Plegridy can lead to changes in blood cell counts, decreasing white cells, red cells, and platelets, which can increase your risk of infections, bleeding, and anemia. Regular blood tests will monitor these levels.
    • There have been reports of thrombotic microangiopathy—blood clots in small vessels—during treatment with Plegridy. Notify your doctor if you notice unusual bruising or bleeding.
    • Some patients may develop pulmonary arterial hypertension, a serious condition affecting the lungs' arteries, during treatment with interferon beta products.
    • Plegridy can trigger or worsen autoimmune responses, leading to conditions like thyroid disorders or hepatitis.
    • Those with a seizure disorder should know that Plegridy might increase the risk of seizures.

    Side Effects

    Plegridy side effects include flu-like symptoms that include headaches, muscle and joint aches, fever, chills, and general fatigue. These symptoms can usually be managed with over-the-counter pain relievers and adequate hydration.

    Plegridy may cause severe allergic reactions characterized by itching, swelling of the face, difficulty breathing, and skin rashes, which require immediate medical attention. Reactions at the injection site such as redness, pain, or swelling may indicate infection or tissue damage. Heart problems, including congestive heart failure and abnormal heartbeats, should be reported to a healthcare provider if symptoms like shortness of breath or leg swelling occur. Plegridy can also affect blood cell counts and liver function, increasing the risk of infection, bleeding, or anemia. Discuss other potential side effects with a healthcare provider.

    References:

    1. Plegridy (Peginterferon) Product Monograph. Cambridge, MA: Biogen Inc.; 2023.
    2. Plegridy (Peginterferon) Drug Label Information. Cambridge, MA: Biogen Inc.; 2023.



    IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

    Product Code : 14915

  • Product Reviews

Processing..

Please wait while the page is loading. Do not hit refresh or the browser back button to avoid any loss of information.

If you have any questions or concerns, please contact our Customer Service team via the chat option on our website or calling us toll free at: 1-800-891-0844